Now that stand-alone HPV tests have been approved, is it worth changing cervical cancer screening recommendations? Juan Felix, MD, weighs in.
Final results of the trial that led to FDA approval show that a new 9-valent HPV vaccine can reduce cases of HPV and cervical cancer.
Adolescent girls who receive the HPV vaccine are no more likely than unvaccinated girls to participate in risky sexual behavior.
Treatments to remove precancerous cervical lesions don't seem to affect a woman's ability to become pregnant, new research found.
Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.
A new human papillomavirus (HPV) vaccine that protects against nine types of HPV and would protect against about 90% of cervical cancers could be available in 2015.
Urine tests effectively screen for HPV, but more data is needed to determine whether they can correctly diagnose cervical disease.
Be it Pap tests, HPV tests, or both, cervical cancer screening is important. This article explores screening paradigms and offers a glimpse of what's to come.
The FDA has approved bevacizumab (Avastin) for treating persistent, recurrent, or metastatic cervical cancer after studies show gains in overall survival.
The optimal time to get the HPV vaccine is before a first sexual encounter. But getting the vaccine after still offers significant protection against cervical dysplasia.